Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2064]

Mechanisms of immune escape in non-Hodgkin lymphoma

Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA

Mechanisms of immune escape in non-Hodgkin lymphoma ( Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA )

Comment on RESONATE2 and CLL115 trials

Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK

Comment on RESONATE2 and CLL115 trials ( Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )

Clinical cases employing novel agents in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA

Clinical cases employing novel agents in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Centre, New York, USA )

Current trials in chronic lymphocytic leukaemia

Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Current trials in chronic lymphocytic leukaemia ( Dr George Follows - Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Microenvironment of chronic lymphocytic leukaemia

Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Microenvironment of chronic lymphocytic leukaemia ( Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Chronic lymphocytic leukaemia: Transition to a new era

Prof Stephen Mulligan - Royal North Shore Hospital, Australia

Chronic lymphocytic leukaemia: Transition to a new era ( Prof Stephen Mulligan - Royal North Shore Hospital, Australia )

Ibrutinib as a frontline therapy in RESONATE2 trials for CLL

Prof Jan Burger, MD Anderson Cancer Center, Texas, USA

Ibrutinib as a frontline therapy in RESONATE2 trials for CLL ( Prof Jan Burger, MD Anderson Cancer Center, Texas, USA )

The role of the microenvironment and novel therapies in CLL

Prof Jan Burger - MD Anderson Cancer Center, Texas, USA

The role of the microenvironment and novel therapies in CLL ( Prof Jan Burger - MD Anderson Cancer Center, Texas, USA )

Editor's Choice for April 2016

Prof Gordon McVie - ecancer Editor

Editor's Choice for April 2016 ( Prof Gordon McVie - ecancer Editor )

Identifying myeloid-driven biologies

Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA

Identifying myeloid-driven biologies ( Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA )

AML17 Trial results: maximum dosage of daunorubicin in AML

Dr Mike Dennis - Christie Hospital NHS Foundation Trust, Manchester, UK

AML17 Trial results: maximum dosage of daunorubicin in AML ( Dr Mike Dennis - Christie Hospital NHS Foundation Trust, Manchester, UK )

AML during pregancy

Dr Sahra Ali - Hull and East Yorkshire Hospitals NHS Trust, Hull, UK

AML during pregancy ( Dr Sahra Ali - Hull and East Yorkshire Hospitals NHS Trust, Hull, UK )

More from ecancer